IRIS
RICCIO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.280
AS - Asia 4.229
EU - Europa 2.812
SA - Sud America 466
Continente sconosciuto - Info sul continente non disponibili 248
AF - Africa 130
OC - Oceania 4
AN - Antartide 1
Totale 12.170
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.102
SG - Singapore 1.772
RU - Federazione Russa 1.304
VN - Vietnam 977
CN - Cina 808
IT - Italia 697
BR - Brasile 346
HK - Hong Kong 227
DE - Germania 155
FR - Francia 153
CA - Canada 98
IE - Irlanda 85
GB - Regno Unito 80
FI - Finlandia 76
NL - Olanda 74
BD - Bangladesh 72
IN - India 67
JP - Giappone 67
MX - Messico 54
AR - Argentina 49
CI - Costa d'Avorio 40
UA - Ucraina 38
ZA - Sudafrica 37
KR - Corea 34
PL - Polonia 31
SE - Svezia 23
IQ - Iraq 22
EC - Ecuador 21
TH - Thailandia 21
PH - Filippine 19
ES - Italia 17
ID - Indonesia 15
PK - Pakistan 15
TR - Turchia 15
CO - Colombia 12
MY - Malesia 12
AT - Austria 11
BG - Bulgaria 11
RO - Romania 10
TW - Taiwan 10
NP - Nepal 9
UZ - Uzbekistan 9
VE - Venezuela 9
KE - Kenya 8
TN - Tunisia 8
UY - Uruguay 8
EG - Egitto 7
IL - Israele 7
KG - Kirghizistan 7
LT - Lituania 7
MA - Marocco 7
PE - Perù 7
CH - Svizzera 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
DZ - Algeria 5
KZ - Kazakistan 5
BE - Belgio 4
BO - Bolivia 4
CR - Costa Rica 4
ET - Etiopia 4
GE - Georgia 4
IR - Iran 4
JO - Giordania 4
NG - Nigeria 4
NO - Norvegia 4
SA - Arabia Saudita 4
BS - Bahamas 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EU - Europa 3
JM - Giamaica 3
KH - Cambogia 3
MN - Mongolia 3
PT - Portogallo 3
AL - Albania 2
AU - Australia 2
AZ - Azerbaigian 2
BH - Bahrain 2
BJ - Benin 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
GY - Guiana 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PA - Panama 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AI - Anguilla 1
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BZ - Belize 1
CU - Cuba 1
Totale 11.902
Salva come PNG Salva come JPEG
Città #
Singapore 822
San Jose 625
Ashburn 384
Moscow 308
Beijing 279
Ho Chi Minh City 242
Chandler 223
Hong Kong 214
Hanoi 181
Santa Clara 149
Hefei 148
Napoli 129
Dong Ket 124
Naples 120
Los Angeles 115
Lauterbourg 85
Millbury 82
Council Bluffs 80
The Dalles 67
New York 63
Munich 59
Tokyo 57
Amsterdam 55
Des Moines 55
Dublin 53
Haiphong 47
Boston 45
Nanjing 42
Buffalo 41
Da Nang 41
Princeton 41
Redondo Beach 41
São Paulo 41
Orem 34
Lawrence 32
Montreal 32
Dallas 29
Milan 28
Caserta 27
Warsaw 26
Atlanta 25
Seoul 25
Wilmington 25
Seattle 24
Mexico City 23
Washington 23
Buenos Aires 22
Frankfurt am Main 21
Helsinki 21
Rome 20
Toronto 20
Hải Dương 19
Johannesburg 19
London 19
Denver 18
Houston 18
Nuremberg 18
Turku 18
Biên Hòa 16
Chennai 16
Phoenix 16
Chicago 15
Jacksonville 15
Poplar 15
Ottawa 14
Stockholm 14
Bangkok 12
Brooklyn 12
Falkenstein 12
Hebei 12
Rio de Janeiro 12
Tianjin 11
Can Tho 10
Long Xuyen 10
Manchester 10
Nanchang 10
New Delhi 10
Redwood City 10
Sciacca 10
Sofia 10
Duncan 9
Düsseldorf 9
Jiaxing 9
Kuala Lumpur 9
San Francisco 9
Tashkent 9
Montevideo 8
Ninh Bình 8
Thái Bình 8
Belo Horizonte 7
Boardman 7
Brasília 7
Campinas 7
Fairfield 7
Nairobi 7
Querétaro 7
Quito 7
Tân Tiến 7
Vĩnh Long 7
Baghdad 6
Totale 6.070
Salva come PNG Salva come JPEG
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 609
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 308
Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients? 194
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 190
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 187
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 174
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 165
Pituitary function and morphology in Fabry disease. 159
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 158
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 154
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 153
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 153
Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. 152
Current tissue molecular markers in colorectal cancer: A literature review 151
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 151
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 150
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 149
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 148
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 148
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 147
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 147
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 146
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 145
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 145
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 144
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 143
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 143
A strange epigastric pain. 143
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 143
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 143
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 143
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 140
ROLE OF HFR CARTRIDGE IN THE REMOVAL OF MEDIATORS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 140
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 140
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 137
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 136
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 135
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 133
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 133
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 131
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 130
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 129
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 129
Optical Coherence Tomography Angiography Findings in Fabry Disease 129
ADPKD and metformin: from bench to bedside 128
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 124
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 122
Clinical manifestation of patients with Fabry disease and R356W GLA variant 121
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 121
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 120
Therapeutic advances in ADPKD: the future awaits 120
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 119
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 118
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 117
Atrial septum aneurysm: an unusual manifestation in ADPKD? 116
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 116
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 115
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 114
Clinical and Pathophysiologic Correlates of Basilar Artery Measurements in Fabry Disease 112
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 111
Renal denervation in ADPKD: an exceptional case 110
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 108
Immunomodulatory Effect of Continuous Venovenous Hemofiltration during Sepsis: Preliminary Data 107
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 106
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family 106
Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease 100
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial 99
Fanconi syndrome with lysinuric protein intolerance 98
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. 98
The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study 95
A pilot study of circulating microRNAs as potential biomarkers of Fabry disease 91
Cardiac involvement in Anderson–Fabry disease. The role of advanced echocardiography 88
Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder 88
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience 87
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients 87
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease 86
Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis 84
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 81
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 80
Cholesterol crystal embolism treatment: from bench to bedside 79
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. 79
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease 78
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial 77
Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? 76
Atheroembolic Kidney Disease and Atypical Hemolytic Uremic Syndrome: Two Sides of the Same Coin? 72
Polycystic pancake kidney 71
New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review 71
Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease 70
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature 69
Semaglutide in Non-Diabetic Patients with Fabry Disease 67
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? 67
Nutritional treatment in chronic kidney disease: the concept of nephroprotection. 65
Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease 65
“Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies” 57
The Case | A patient with autosomal dominant polycystic kidney disease with an atypical kidney magnetic resonance image 53
The potential use of biomarkers in predicting contrast-induced acute kidney injury. 52
Acute Kidney Injury in COVID-19 Pandemic 51
Trimethoprim-sulfamethoxazole prophylaxis inantineutrophil cytoplasmic antibody-associatedvasculitis: watch out for pseudoacute kidney injury: comment on the article by Kim et al (Tme‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study) 50
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin 46
Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis 19
Totale 12.154
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.092
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.092
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022446 0 0 5 4 7 11 28 18 33 52 116 172
2022/2023571 75 44 26 41 55 69 9 57 97 53 30 15
2023/2024561 23 92 41 38 35 76 6 62 15 12 118 43
2024/20252.752 125 97 23 54 53 187 262 161 202 275 1.049 264
2025/20266.288 666 474 570 610 1.118 249 688 329 598 481 371 134
2026/2027552 524 28 0 0 0 0 0 0 0 0 0 0
Totale 12.170